Qiagen and Eppendorf form alliance

Friday, 03 February, 2006

Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.

In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.

Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.

Related News

Horizon Europe negotiations conclude

Once associated, Australian researchers and entities will be able to access Horizon Europe...

AusBiotech responds to Budget 2026–27

The life sciences industry body has responded to measures set out in the Australian...

AI.gov.au launches to help safe and responsible AI use

Providing guidance, tools and resources to help Australian businesses use AI safely, the...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd